Adelhoefer Siegfried, Uddin S M Iftekhar, Osei Albert D, Obisesan Olufunmilayo H, Blaha Michael J, Dzaye Omar
Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease (S.A., S.M.I.U., A.D.O., O.H.O., M.J.B., O.D.) and Russell H. Morgan Department of Radiology and Radiological Science (O.D.), Johns Hopkins University School of Medicine, 600 N Wolfe St, Blalock 524, Baltimore, MD 21287; Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Md (A.D.O.); and Department of Radiology and Neuroradiology, Charité, Berlin, Germany (S.A., O.D.).
Radiol Cardiothorac Imaging. 2020 Dec 17;2(6):e200281. doi: 10.1148/ryct.2020200281. eCollection 2020 Dec.
Coronary artery calcium (CAC) is a highly specific marker for coronary atherosclerosis. The CAC Consortium, a multicenter, retrospective, real-world cohort study, was established to investigate the association between CAC and long-term, cause-specific mortality. This review summarizes findings from CAC Consortium studies published between 2016 and 2020, aiming to demystify CAC as a clinical decision-guiding tool and push the limits of who might benefit from CAC in clinical practice. CAC has been shown to effectively stratify cardiovascular risk across ethnicities irrespective of age, sex, and risk factor burden. In comparison to other widely used risk scores, CAC appears to be most consistent in its ability to add to cardiovascular disease (CVD) event prediction. Beyond risk stratification, CAC has been shown to identify high-risk patient subgroups. While currently recommended only for patients at borderline or intermediate risk by the American College of Cardiology/American Heart Association (10-year atherosclerotic CVD event risk, 5% to < 20%), CAC scoring may also provide value in select young patients aged 30-49 years and in low-risk patients with a family history. While new studies emphasize that patients with a CAC greater than or equal to 1000 be considered a distinct patient group, a CAC of 0 has additionally emerged to be a reliable negative risk factor, identifying patients at low risk of both CVD and non-CVD mortality. © RSNA, 2020.
冠状动脉钙化(CAC)是冠状动脉粥样硬化的一种高度特异性标志物。CAC联盟是一项多中心、回顾性、真实世界队列研究,旨在调查CAC与长期、特定病因死亡率之间的关联。本综述总结了2016年至2020年间发表的CAC联盟研究结果,旨在揭开CAC作为临床决策指导工具的神秘面纱,并拓展其在临床实践中可能使哪些人受益的范围。研究表明,无论年龄、性别和危险因素负担如何,CAC都能有效地对不同种族的心血管风险进行分层。与其他广泛使用的风险评分相比,CAC在增加心血管疾病(CVD)事件预测能力方面似乎最为一致。除了风险分层外,CAC还被证明可识别高危患者亚组。虽然目前美国心脏病学会/美国心脏协会仅推荐对临界或中度风险患者(10年动脉粥样硬化性CVD事件风险为5%至<20%)使用CAC评分,但在某些30 - 49岁的年轻患者和有家族史的低风险患者中,CAC评分也可能具有价值。虽然新的研究强调,CAC大于或等于1000的患者应被视为一个独特的患者群体,但CAC为0也已成为一个可靠的负性风险因素,可识别CVD和非CVD死亡风险均较低的患者。©RSNA,2020。